Causes of TEN and SJS
In 74%-94% of cases, TEN is triggered either by preceding medication or by an infection of the upper respiratory tract (13-16).
The first large study to assess the risk of developing SJS or TEN included 245 TEN-patients and 1,147 controls (17). This study distinguished between drugs usually used for short-term periods and drugs used for months or years. The highest risk in the first group was documented for trimethoprim-sulfomethoxazole and other sulfonamide antibiotics (crude relative risk [RR] 172), followed by chlormezanone (crude RR 62), cephalosporins (multivariate RR 14), quinolones (multivariate RR 10), and aminopenicillins (multivariate RR 6.7). For acetaminophen, the RR was calculated to be 0.6 in France but up to 9.3 in other countries. In the long-term-use group, the increased risk was confined largely to the first 2 months of treatment. Crude RRs of other drugs were 90 for carbamazepine followed by oxicam-nonsteroidal antiinflammatory drugs (RR 72), corticosteroids (RR 54), phenytoin (RR 53), allopurinol (RR 52), phenobarbital (RR 45), and valproic acid (RR 25) .
The large EuroSCAR study (18) analyzed RRs for several drugs. Among the newer drugs, strong associations were documented for nevirapine (RR Ͼ22), tramadol (RR ϭ 20), pantoprazole (RR ϭ 18), lamotrigine (RR Ͼ14), and sertraline (RR ϭ 11). Analysis of older drugs largely confirmed the results from Roujeau et al (17) and showed the following univariate RRs: cotrimoxazole, 102; sulfonamides, 53; carbamazepine, 33; phenytoin, 26; phenobarbital, 17; allopurinol, 11; and oxicam-nonsteroidal anti-inflammatory drugs, 6.4.
Both of these studies included children and adults, with Ͻ10% of cases occurring in children. A pooled analysis was performed for children of Ͻ15 yrs (19). The univariate analysis showed that antiinfective sulfonamides, phenobarbital, lamotrigine, and carbamazepine were strongly associated with SJS/TEN in children. Valproic acid, acetaminophen, and nonsteroidal anti-inflammatory drugs as a group also increased the risk of SJS/TEN.
Cross-reactivity of drugs might lead to fatal recurrent TEN (20) . Potential crossreactivity among ␤-lactam antibiotics and cephalosporins exists. Similarly cross-reactivity and recurrence of disease might occur after administration of antiepileptic drugs with the arene-oxide moiety (e.g., phenytoin, phenobarbital, carbamazepine, etc.) and application of other antiepileptics (e.g., valproic acid, levetiracetam, etc.) should be considered.
Other factors associated with SJS/TEN are infectious diseases such as those caused by human immunodeficiency virus (21), herpesvirus, Mycoplasma pneumoniae (22-25), and hepatitis A virus (26) and noninfectious conditions including radiotherapy (27, 28), lupus erythematosus (29, 30), and collagen vascular disease (31).
Genetics
Several genetic factors influence the risk of developing TEN/SJS. A statistically significant increase in human leukocyte antigen (HLA)-B12 phenotype among 44 patients surviving TEN was documented (32).
In Han Chinese, two other gene loci have been shown to increase risk for TEN: HLA-B*5801 was present in all patients with severe cutaneous reactions to allopurinol and in only 15% of 135 tolerant patients (33).
HLA-B*1502 was present in all Chinese patients experiencing carbamazepine-induced SJS, while HLA-B*1502 was detected in only 3% of carbamazepine-tolerant patients (34). The risk of carbamazepine-induced SJS/TEN was significantly higher in Thai patients with HLA-B*1502 (35) and in Indian patients (36).
Carbamazapine-induced SJS/TEN was strongly associated with HLA-B*1502 in Chinese patients but patients with carbamazepine-induced maculopapular eruptions had an odds ratio similar to tolerant controls (37). In a European study of 12 patients with carbamazepine-induced SJS/ TEN, only four had the HLA-B*1502 allele (38). Remarkably, these four patients had an Asian ancestry, whereas the others did not. This shows that HLA-B*1502 seems to be a useful predictive marker in the Asian population but not in European patients. An HLA-B*1502 screening before treatment with carbamazepine in Asian patients was proposed (39).
Immunopathogenesis
The etiology of TEN is not completely understood. Several theories including immunologic mechanisms, reactive drug metabolites, or interactions between these two have been published in a review (40).
In summary, specific drug hypersensitivity leads to major histocompatibility class I-restricted drug presentation and is followed by an expansion of cytotoxic Tlymphocytes, leading to an infiltration of skin lesions with cytotoxic T-lymphocytes and natural killer cells.
Evidence is supportive of a role for the death receptor Fas and its Fas ligand (CD95) in the pathogenesis of keratinocyte apoptosis during TEN (41). Other findings suggest activation of the perforin/granzyme pathway as a cytotoxic mechanism in SJS/TEN (42).
Recent publications show that granulysin probably is the key mediator for disseminated keratinocyte death in SJS/ TEN. Granulysin levels in the sera of patients with SJS/TEN are much higher than in patients with ordinary druginduced skin reactions or healthy controls (43). Furthermore granulysin levels correlate with clinical severity (44).
Since the mechanism is not IgE mediated, a desensitization of the triggering drug is not an option.
Clinical Course
Drug-induced TEN typically presents with fever and influenza-like symptoms 1 to 3 wks after the application of the suspected drug (45). One to 3 days later, signs begin in the mucous membranes, including eyes, mouth, nose, and genitalia in up to 90% of cases. Skin lesions manifest as generalized macules with purpuric centers. The macules progress to large confluating blisters with subsequent epidermal detachment, yet never show involvement of the hair (Fig. 1) . In the following 3 to 5 days, separation of the epidermis progresses and leads to large denuded areas (Fig. 2) . The large wound area leads to extreme pain, massive loss of fluid and protein, bleeding, evaporative heat loss with subsequent hypothermia, and infection (46).
Histopathology shows separation of the epidermis at the dermal-epidermal junction of the skin, extracutaneous epithelium, and mucous membranes. Clinically, this can be detected by a positive Nikolsky sign, which describes detachment of the full-thickness epidermis when light lateral pressure is applied with the examining finger. Unlike the situation in full-thickness burns, the epidermal appendages remain largely intact, which allows re-epithelialization without scarring. Re-epithelialization of the epidermis begins about 1 wk after onset of skin reactions and takes up to 3 wks (47).
Gastrointestinal involvement frequently occurs in the mouth and esophagus but also in the small bowl and colon (48 -50). Patients with TEN usually do not develop a paralytic ileus, which allows early enteral nutrition (51). Involvement of the gastrointestinal tract may lead to stenosis or strictures and consecutive long-term complications with dysphagia and ileus-like symptoms. Vulvovaginal involvement may also lead to vaginal stenosis or strictures (52, 53).
Hyper-and hypopigmentation occur in virtually all children and tend to fade with time but usually do not resolve completely (Fig. 3) . Hypertrophic changes and scarring of the skin occur infrequently (54). Long-term sequelae also involve fingernails and toenails, usually after inflammation of the nail beds and loss of the nails during the acute phase of TEN. Nails can develop deformities that are usually not painful and not associated with significant functional disability.
In TEN, pulmonary edema and progressive respiratory failure develop within the first days and large ulcerations and epithelial necrosis of the bronchial epithelium occur, which has to be suspected when dyspnea, bronchial hypersecretion, normal chest radiograph, and hypoxemia are present during the early stages of the disease (55).
Intubation and mechanical ventilation may be required and is associated with higher mortality (56). Permissive hypercapnia with moderate respiratory acidosis (pH Ͼ7.20) can help to prevent barotrauma and ventilator-induced lung injury (57). Treatment with inhaled nitric oxide might be helpful. PaO 2 /FIO 2 ratio improved an average of 162% after administration of low-dose inhaled nitric oxide (average 6.7 ppm), but nonsurvivors had a significantly less favorable initial response (58).
SJS/TEN survivors may have persistent respiratory sequelae and a reduction in carbon monoxide diffusing capacity of up to 35%-40% below normal even if they did not require mechanical ventilation (59).
Ophthalmic complications are seen in about 30% of the surviving children, up to 74% in adults (60), and are severe in 25% of cases (61).
The acute stage of ophthalmic involvement persists 2 to 6 wks and shows swollen and erythematous eyelids, bacterial conjunctivitis, suppurative keratitis, or endophthalmitis. If there is significant inflammation, topical steroids can reduce the circle of cicatrization and eyelid deformities (62). Extensive scarring due to overgrowth with conjunctival epithelium, membranous or pseudomembranous conjunctivitis, ankyloblepharon, or symblepharon with additional complications like entropion or lagophthalmos leads to a severe dry eye syndrome or loss of vision.
Persistent inflammation and ulceration may lead to the destruction of limbal stem cells and stem cell deficiency (63, 64). Even after limbal stem cell transplantation, the prognosis is poor (65). Chronic ophthalmic complications occur more frequently in patients with initial ocular involvement (60), but loss of vision due to chronic corneal inflammation also occurs in patients without initial affection of the eye and is considered to be the most severe long-term complication in TEN/SJS survivors (61).
Long-term treatment with steroids and vigorous lubrication helps to prevent late complications such as impaired tear production, aberrant lashes, and metaplasia. Photophobia occurs frequently and may resolve gradually over months (61, 66 -68).
Amniotic membrane transplantation has been increasingly performed in recent years and may prevent chronic complications. A recent review shows good results in six children (69).
Other organ manifestations occur rarely. Involvement of the kidneys with glomerulonephritis, tubulonecrosis, and pancreatitis (70), as well as involvement of the liver including hepatocellular necrosis or cholestasis, has been reported (71-75).
The mortality of SJS is estimated to be 1%-3% (13). In contrast, mortality rates for TEN are between 30% and 50% (76, 77), with death usually resulting from sepsis or multiorgan failure (13, 45, 78). The mortality rate of children appears to be lower than that of adults.
A severity-of-illness score for TEN (SCORTEN) was published (79). This score combined seven independent risk factors for mortality (age Ն40 yrs, heart rate Ն120/min, history of cancer or hematologic malignancies, involved body surface area Ͼ10%, serum urea level Ͼ10 mmol/L, serum bicarbonate level Ͻ20 mmol/L, serum glucose level Ͼ14 mmol/L). Scoring one point for each item, the predicted mortality was 3.2%, 12.1%, 5.3%, 58.3%, and 90.0% for 0 -1, 2, 3, 4, and Ն5 points respectively. The predicted mortality was shown to be accurate by other publications (80, 81) but may underestimate mortality in patients with respiratory involvement (82) . Others published a lower mortality rate with a standardized treatment protocol (83) or analyzed that body surface involvement and age probably need more weight in calculations (84) .
Treatment
Immediate discontinuation of the triggering drug reduces mortality and improves prognosis (85, 86) . Readministration of the suspected drug can cause a relapse of TEN (87) .
The management of TEN is similar to the treatment of extensive burns, and several studies have demonstrated that early transfer to a burn unit reduces morbidity and mortality significantly: TEN survivors had been transferred to a burn unit 7.5 days earlier than nonsurvivors with a mortality of 4% vs. 83%. Bacteremia, septicemia, and length of hospitalization were also reduced with early transfer (88) . The largest trial showed a mortality of 29.8% after transfer to a burn center within 7 days vs. 51.4% (p Ͻ .05) after 7 days (89) . Other studies largely support early transfer to a burn unit (85, 90 -93) .
However, several differences between TEN and burns need to be respected. In TEN, which in contrast to burns affects only the superficial dermal layers, fluid, electrolyte, and energy requirements are usually lower than in burns of the same extent (90) . Initial provision of 2 mL/kg/% affected body surface area results in adequate urine output and significant correction of blood pressure in adults (94) .
Older studies suggest that nutritional requirements are similar to those in burn injury (95) (96) (97) , but newer studies show that pediatric SJS/TEN patients require approximately 600 calories or 22% less per day than patients with burns (98) . A statistically generated equation estimating the energy requirement in the pediatric SJS/TEN population was developed: caloric needs ϭ (preinjury weight
Other authors suggested that energy intake of 120% of the predicted basal metabolic rate and intake of 3 grams per kilogram protein result in adequate wound healing, whereas higher energy provisions enhance weight status (99) .
Negative prognostic factors are hypernatremia (100), increased blood urea nitrogen, neutropenia, thrombocytopenia, visceral involvement, and delayed presentation (14, 90, 101).
Besides providing adequate analgesia, it is also essential to prevent dehydration and superinfection. Treatment of the skin lesions with antimicrobial materials like copper sulfate (102) , silver nitrate (103), or sulfadiazine cream (which contains sulfonamide and might lead to crossreactivity with sulfonamide antibiotics) and covering with biological or synthetic materials have been proposed. In less developed countries, banana leaf dressings and boiled potato peel bandage may cover wounds satisfactorily (104) . Porcine xenograft skin and human allograft cadaveric skin have been used, but there is a trend to nonadherent (semi-)synthetic materials. For example, Biobrane has been used with good results and showed reduced pain and improved mobilization in elderly patients (105) (106) (107) . Other materials like Acticoat, Aquacel Ag, or Suprathel are synthetic materials containing nanocrystalline silver, which serves as an antimicrobial agent and is released for up to 7-14 days. The need of painful dressing changes can be reduced. Several case reports, including one case of a young infant, show good results (108 -113) .
Additionally, it can be helpful to prevent shear forces and other mechanical disruptions to prevent further areas of skin desquamation (114) .
Considering the immunologic background of TEN, treatment with immunosuppressive drugs was expected to be beneficial.
Corticosteroids inhibit a wide range of intracellular processes in turn modifying the inflammatory and immune response and have been used in the management of SJS and TEN for Ͼ30 yrs.
Several reports have been published showing benefits of corticosteroid treatment. In a randomized prospective trial, pediatric patients treated with methylprednisolone showed a significantly shorter duration of fever than did others with supportive care only (115) .
However, other analyses suggest increased mortality and morbidity. Pediatric patients with SJS treated with high doses of corticosteroids did not recover sooner than those treated with supportive care alone. Patients in the steroid group had a higher incidence of medical complications (53% vs. 0%), most commonly infection (24%) and gastrointestinal bleeding (21%) (116) .
Mortality was significantly higher in a steroid treated group with 66% vs. 33% in the nonsteroid group (103) . Administration of corticosteroids for Ͼ48 hrs was associated with a higher rate of infection, longer hospitalization, and increased mortality rate. A multivariate analysis documented that treatment with corticosteroids is an independent risk factor for increased mortality (88) .
However, a recently published large retrospective study included 281 patients and evaluated the treatment of corticosteroids and intravenous immunoglobulins (IVIGs) either alone or in combination compared to supportive care only. Neither intravenous immunoglobulins nor corticosteroids showed any significant effect on mortality in comparison with supportive care (117) .
Publications evaluating the treatment of TEN or SJS with corticosteroids are summarized in Table 2 .
In vitro studies showed that intravenous immunoglobulin was able to block the Fas receptor (41), which was the rationale for the therapeutic use of immunoglobulins geared toward the inhibition of apoptosis.
Cessation of cutaneous blistering was observed in all patients within an average of 2 days after IVIG was initiated. No correlation between the timing or dosing and time to objective response was identified in pediatric patients with SJS or TEN (118) .
A retrospective trial compared treatment with IVIGs to standard supportive care (119) . The survival was 88%, and the authors recommended a dose of 1 g/kg/ day for 3 days. Other studies with combined 32 patients reported a survival of 100% (120 -122) . IVIG-treated patients showed a shorter duration of fever and shorter hospitalization (123) .
These optimistic results have not been confirmed by several other studies: a retrospective chart review found a higher mortality and a longer hospitalization in patients treated with IVIGs (124) . Other studies showed no significant difference in mortality, multiorgan failure, duration of mechanical ventilation, severity of systemic inflammation, incidence of sepsis, time to recovery or length of stay in hospital (125) , or in progression of detachment or speed of re-epidermalization (126) . The largest trial included 281 patients and did not show decreased mortality with IVIGs (117) . Table 3 summarizes studies with treatment of TEN or SJS with IVIGs. In summary, the specific treatment of SJS/ TEN with immunoglobulins remains controversial, and large randomized controlled trials are needed.
The only double-blind, randomized, placebo-controlled trial concerning treatment of TEN was performed for thalidomide (127) . Thalidomide inhibits the production of tumor necrosis factor alpha and interleukin-6 secreted by monocytes and lymphocytes. The progression of skin reaction was similar in both groups, but mortality was increased in the thalidomide group (83%) vs. placebo (30%), which led to the discontinuation of the study. Thus, thalidomide cannot be considered a safe or effective treatment of TEN.
Cyclosporine inhibits CD8 activation and also has antiapoptotic activity. Theoretically, this inhibits epidermal apoptosis and leads to improved outcome. To date, large trials have not been performed, but several case reports with up to 29 patients have been published using cyclosporine 3-10 mg/kg daily (128 -137) . Patients treated with cyclosporine had a significantly shorter time until stop of progression and complete re-epithelialization. Failure of Ն4 organs and severe leukopenia and mortality were also significantly less frequent in the cyclosporine group (138). Overall, cyclosporine treatment seems promising, but larger trials are needed to confirm the preliminary results.
Abnormal inherited metabolic pathways are presumed in some cases, which could lead to a diminished detoxifying capacity. Administration of N-acetylcysteine enhances the oxidant buffering capacity of glutathione and inhibits nuclear factor kappa B, a transcription factor induced by tumor necrosis factor alpha and interleukin-6 (139). Treatment with N-acetylcysteine has been published with good results (140, 141) , but numbers are small and controlled trials have not been performed.
Plasmapheresis has been used in several case reports and small studies, mostly in adult patients but also in children as young as 1 yr. The procedure can be considered safe. One to eight plasma exchange sessions have been used, predominantly with good results (142) (143) (144) (145) (146) (147) (148) .
Infliximab (149 -154) , azathioprine (155), methotrexate (156), cyclophosphamide (157-160), and recombinant granulocyte colony-stimulating factor (161) (162) (163) were also used for the treatment of TEN, but the data are limited and need further evaluation.
Since most studies have been performed in adult patients and treatment of TEN and SJS in pediatric patients has not been studied extensively, we provide an overview of all larger studies performed in pediatric patients in Table 4 .
CONCLUSION
TEN is a life-threatening exfoliative skin disease that shows blistering and extensive shedding of the skin, and finally presents with large denuded areas. Other organs are frequently affected, and an interdisciplinary team is needed to provide optimal therapy. Although the incidence is relatively low, it is important to identify patients at risk to avoid delaying therapy. Treatment modalities vary widely between supportive care alone, specific treatment with immunosuppressive drugs, IVIGs, and plasmapheresis. To date, no treatment has been shown to be superior, but in almost all cases no prospective randomized controlled trials have been performed. 
